BIRC2 and cancer: It is noteworthy that the lack of responses seen with BI 891065 in these studies could be partly because the populations enrolled were heavily pretreated (median 3.5–5 prior lines of therapy), had advanced‐stage cancers and were not screened for the presence or absence of the target molecule, cIAP1.